MREO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mereo BioPharma Group PLC (MREO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock faces significant challenges, including poor trial results, multiple downgrades from analysts, ongoing legal issues, and weak financial performance. Additionally, there are no strong positive catalysts or proprietary trading signals to support a buy decision.
The technical indicators show a bearish trend with moving averages in a downward pattern (SMA_200 > SMA_20 > SMA_5). The MACD is slightly positive but contracting, and RSI is neutral at 33.083. The stock is trading near its support level of 0.328, with resistance at 0.365. Overall, the technical analysis does not indicate a strong buy signal.
NULL identified. The only slight positive is the potential for bone mineral density improvements in trials to support a regulatory path, but this is highly uncertain.
Poor Phase 3 trial results for setrusumab, missing primary endpoints.
Multiple analyst downgrades and significant reductions in price targets.
Ongoing legal issues with class action lawsuits related to misleading information.
Weak financial performance with no revenue growth, negative net income, and declining EPS.
In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of $7.35 million, and a significant EPS decline of -83.33% YoY. Gross margin remained flat at 73.4%. Overall, the financials are weak and do not support a buy decision.
Analyst sentiment is overwhelmingly negative. JPMorgan downgraded the stock to Neutral, citing regulatory uncertainty. Other firms, including Cantor Fitzgerald, BTIG, and Jefferies, have significantly lowered price targets and downgraded ratings due to poor trial results and reduced probability of success for key drugs in the pipeline.
